Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study

National Health Research Institutes, Taiwan

Status and phase: Terminated; Phase 2

Conditions: Gastric Adenocarcinoma

Treatments: Drug: Capecitabine, Oxaliplatin, Docetaxel

Study type: Interventional

Funder types: Other

Identifiers

NCT01558011

100CT202 (Other Grant/Funding Number)

T3211

Details and patient eligibility

About

This is an open-label, non-comparative phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma.

Full description

There are two primary objectives in different steps. In the first step, the primary objective of this study is to investigate the objective response rate in patients receiving sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma.

In the second step, the primary objective of this study is to screen the predictive biomarkers of three different chemotherapeutic drugs and also investigate the objective response rate in patients receiving sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma.

Enrollment: 51 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed gastric adenocarcinoma.
• At least one measurable lesion in a non-irradiated area.
• No prior exposure to systemic chemotherapy for advanced gastric cancer.
• For those have adjuvant chemotherapy after a curative gastrectomy, the last dosing of previous adjuvant chemotherapy should be at least 6 months before the start of this treatment.
• Age > 20 years old.
• ECOG Performance Status 2.
• Life expectancy greater than 12 weeks.
• Adequate bone marrow function :absolutely neutrophil count 1.5 x 109/L or WBC 4 x 109/L; Hemoglobin > 9 g/dl;platelet count 100 x 109/L.
• Adequate liver function : ALT & AST 2.5 x ULN if without liver metastasis or 5 x ULN if with hepatic metastasis. Alkaline phosphatase 2.5 x ULN if without liver metastasis or 5 x ULN, if with hepatic and bone metastasis. Bilirubin < 2 x ULN
• Adequate renal function :Creatinine < 1.5 x ULN.
• Patients must be accessible for treatment and follow-up in the participating centers.

Exclusion criteria

• Patient who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy.(Previous radiotherapy is allowable if the last dose was given more than 2 weeks before the protocol treatment).
• Major surgery within two weeks prior to entering the study.
• Patients with CNS metastasis, including clinical suspicion.
• Patients who are under active or uncontrolled infections.
• Patients who had cardiac arrhythmia or myocardial infarction history 6 months before entry.
• Patients with clinically detectable peripheral neuropathy > 2 on the CTC criteria
• Patients with concomitant illness that might be aggravated by chemotherapy.
• Patients who are pregnant or with breast feeding.
• Other concomitant or previously malignancy within 5 yrs except for in situ cervix cancer or squamous cell carcinoma of the skin treated by surgery only.
• Patients with hypersensitivity to any component of the chemotherapeutic regimen.
• Mental status is not fit for clinical trial
• Can not take study medication orally

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

51 participants in 1 patient group

chemotherapy

Experimental group

Description:

Chemotherapy: Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy.

Treatment:

Drug: Capecitabine, Oxaliplatin, Docetaxel